Needham & Company LLC Lowers Regado Biosciences Price Target to $13.00 (RGDO)
Analysts at Needham & Company LLC cut their target price on shares of Regado Biosciences (NASDAQ:RGDO) from $16.00 to $13.00 in a research report issued to clients and investors on Thursday, Analyst Ratings.Net reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price indicates a potential upside of 139.41% from the stock’s previous close.
Regado Biosciences (NASDAQ:RGDO) traded down 3.87% on Thursday, hitting $5.22. 72,370 shares of the company’s stock traded hands. Regado Biosciences has a 1-year low of $4.27 and a 1-year high of $14.10. The stock’s 50-day moving average is $7.72 and its 200-day moving average is $6.7. The company’s market cap is $175.4 million.
Regado Biosciences (NASDAQ:RGDO) last announced its earnings results on Wednesday, May 14th. The company reported ($1.30) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.62) by $0.68. On average, analysts predict that Regado Biosciences will post $-2.36 earnings per share for the current fiscal year.
A number of other firms have also recently commented on RGDO. Analysts at Deutsche Bank initiated coverage on shares of Regado Biosciences in a research note on Friday, April 25th. They set a “buy” rating and a $14.00 price target on the stock. Analysts at BMO Capital Markets reiterated a “positive” rating on shares of Regado Biosciences in a research note on Monday, March 10th. Six equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $13.00.
Regado Biosciences, Inc is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.